Should You Add Teleflex Stock to Your Portfolio Now?

Teleflex’s TFX Interventional arm portfolio is well positioned for sustained growth, led by clinical development. Sustained demand for central access and hemostatic products, coupled with new product introductions such as EZPLAZ, should support continued growth in the Vascular business. A strong solvency looks encouraging. Yet, unfavorable FX remains a key concern for Teleflex.

Over the past year, this Zacks Rank #2 (Buy) stock has gained 9.1% against the industry’s 3.3% decline. The S&P 500 composite has risen 20% during the same period. 

The global provider of medical technologies has a market capitalization of $5.52 billion. TFX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.2%. 

Let’s delve deeper.

Tailwinds for Teleflex

Vascular Business Grows: The Vascular portfolio continues to benefit from demand in central access and hemostatic products. In the second quarter of 2026, Vascular revenues rose 9% on a reported basis and 8% on a pro forma adjusted constant-currency basis. Management said the team managed through the lidocaine recall and related back orders during the second quarter, although distributor inventories had moved higher and were expected to normalize in the second half. Product development also supports the longer-term case. 

In late July 2026, the FDA approved EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma licensed by the agency, expanding Teleflex's emergency medicine offering within Vascular. Management characterized the underlying Vascular market as a mid-single-digit growth market, supporting a durable demand backdrop beyond near-term ordering patterns.

Interventional Platform Expands: Teleflex has broadened its Interventional platform through the BIOTRONIK Vascular Intervention acquisition, adding drug-coated balloons, stents and balloon catheters while expanding its geographic reach. Management continues to view the acquired and legacy portfolios as complementary, with opportunities to gain market share, expand geographically and launch new products as integration progresses through the second half of 2026.

Several categories, including hemostatic products, right heart catheters, intraosseous and complex catheters, performed well in the second quarter. Teleflex also advanced the clinical development of Freesolve, its drug-eluting resorbable magnesium scaffold. Four-year follow-up data from the BIOMAG-I study showed sustained performance and a favorable long-term safety profile. 

The BIOMAG-II enrollment was completed ahead of schedule, supporting a late-2027 data readout, while the U.S. BIOMAG-III pivotal trial began in June 2026. These developments expand the company’s exposure to interventional procedures and support the platform's longer-term growth potential.

Image Source: Zacks Investment Research

Balance Sheet Flexibility Improves: Teleflex exited the second quarter of 2026 with cash and cash equivalents of $300.2 million. Current borrowings totaled $87.5 million, remaining well below the corresponding cash balance. Long-term borrowings amounted to $2.72 billion at the end of the second quarter. 

Following the OEM divestiture, pro forma net leverage declined to about 1.9X from 2.8X at quarter-end, as Teleflex used proceeds to repay the $700 million Term Loan A-2. The company continues to target about $800 million of debt reduction from strategic divestiture proceeds, which should strengthen balance sheet flexibility and reduce interest expense.

What Ails TFX Stock?

Foreign Exchange Sensitivity: Teleflex’s international operations remain exposed to currency movements that can affect revenues and earnings. Although its 2026 guidance assumes an approximately 0.7% positive foreign exchange impact on GAAP revenue growth, that benefit could reverse as exchange rates change. The company uses cross-currency swaps and other hedging instruments, but these measures do not fully eliminate translation and transaction effects. As a result, currency volatility remains a risk to reported growth and earnings consistency.

TFX Stock Estimate Trend

The Zacks Consensus Estimate for TFX’s 2026 earnings per share (EPS) has increased 4.4% to $6.84 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $2.28 billion, implying a 23.1% decline from the year-ago reported number.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Globus Medical GMED, Veracyte VCYT and Illumina ILMN.

Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Illumina, presently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research